Cargando…

Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis

OBJECTIVE: To evaluate the effect of dimethyl fumarate (DMF; Tecfidera, Biogen, Weston, MA) on CD4(+) and CD8(+) T cell subsets in patients with multiple sclerosis (MS). METHODS: Peripheral lymphocyte subsets, including CD4(+) and CD8(+) memory cells and T helper (T(H)) cells T(H)1, T(H)2, T(H)17, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gross, Catharina C., Schulte-Mecklenbeck, Andreas, Klinsing, Svenja, Posevitz-Fejfár, Anita, Wiendl, Heinz, Klotz, Luisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4701136/ https://www.ncbi.nlm.nih.gov/pubmed/26767188 http://dx.doi.org/10.1212/NXI.0000000000000183

Ejemplares similares

Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)
por: Klotz, Luisa, et al.
Publicado: (2015)

Effects of Blood Transportation on Human Peripheral Mononuclear Cell Yield, Phenotype and Function: Implications for Immune Cell Biobanking
por: Posevitz-Fejfár, Anita, et al.
Publicado: (2014)

Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunity
por: Liebmann, Marie, et al.
Publicado: (2021)

Fingolimod treatment promotes regulatory phenotype and function of B cells
por: Grützke, Berit, et al.
Publicado: (2015)

Immune Cell Profiling During Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of Non-T Cell Populations into the Cerebrospinal Fluid—Results from the ToFingo Successor Study
por: Lohmann, Lisa, et al.
Publicado: (2018)

Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis
por: Gross, Catharina C., et al.
Publicado: (2016)

Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis
por: Buckle, Guy, et al.
Publicado: (2020)

Regulatory Functions of Natural Killer Cells in Multiple Sclerosis
por: Gross, Catharina C., et al.
Publicado: (2016)

Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2022)

Generation of a Model to Predict Differentiation and Migration of Lymphocyte Subsets under Homeostatic and CNS Autoinflammatory Conditions
por: Gross, Catharina C., et al.
Publicado: (2020)

Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets
por: Lundy, Steven K., et al.
Publicado: (2016)

Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study
por: Ruck, Tobias, et al.
Publicado: (2019)

Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis
por: Eschborn, Melanie, et al.
Publicado: (2021)

Impact of disease‐modifying therapies on humoral and cellular immune‐responses following SARS‐CoV‐2 vaccination in MS patients
por: Trümpelmann, Susan, et al.
Publicado: (2022)

Immune Cell Profiling of the Cerebrospinal Fluid Provides Pathogenetic Insights Into Inflammatory Neuropathies
por: Heming, Michael, et al.
Publicado: (2019)

Effectiveness and safety of dimethyl fumarate in progressive multiple sclerosis
por: Moreira Ferreira, Vanessa F, et al.
Publicado: (2021)

Immune signatures of prodromal multiple sclerosis in monozygotic twins
por: Gerdes, Lisa Ann, et al.
Publicado: (2020)

Dimethyl fumarate–induced lymphopenia in MS due to differential T-cell subset apoptosis
por: Ghadiri, Mahtab, et al.
Publicado: (2017)

High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients
por: Schneider-Hohendorf, Tilman, et al.
Publicado: (2020)

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
por: Laplaud, David-Axel, et al.
Publicado: (2019)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

COVID‐19 in dimethyl fumarate‐treated patients with multiple sclerosis
por: Mantero, Vittorio, et al.
Publicado: (2020)

COVID-19 in multiple sclerosis patients treated with dimethyl fumarate
por: Capone, Fioravante, et al.
Publicado: (2021)

Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells
por: Ruck, Tobias, et al.
Publicado: (2018)

Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation
por: Rolfes, Leoni, et al.
Publicado: (2021)

Protective potential of dimethyl fumarate in a mouse model of thalamocortical demyelination
por: Cerina, Manuela, et al.
Publicado: (2018)

Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate
por: Baharnoori, Moogeh, et al.
Publicado: (2016)

The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis
por: Dupuy, Sheena L., et al.
Publicado: (2016)

The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
por: Wicks, Paul, et al.
Publicado: (2016)

Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis
por: Mills, Elizabeth A., et al.
Publicado: (2018)

Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2020)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis
por: Norborg, Hilde, et al.
Publicado: (2021)

Dimethyl Fumarate Reduces Inflammation in Chronic Active Multiple Sclerosis Lesions
por: Zinger, Nicole, et al.
Publicado: (2022)

No Changes in Functional Connectivity After Dimethyl Fumarate Treatment in Multiple Sclerosis
por: Piervincenzi, Claudia, et al.
Publicado: (2022)

Effects Mediated by Dimethyl Fumarate on In Vitro Oligodendrocytes: Implications in Multiple Sclerosis
por: Guerriero, Claudia, et al.
Publicado: (2022)

Dimethyl fumarate for ischemic stroke
por: Kunze, Reiner
Publicado: (2017)

Functional subsets of circulating follicular helper T cells in patients with atherosclerosis
por: Ghamar Talepoor, Atefe, et al.
Publicado: (2020)

Gut–CNS-Axis as Possibility to Modulate Inflammatory Disease Activity—Implications for Multiple Sclerosis
por: Fleck, Ann-Katrin, et al.
Publicado: (2017)

Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate
por: Spencer, Collin M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_a1m4otu6ckoh8fg1qo256up86c